Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma

C. Kurokawa, H. Geekiyanage, C. Allen, I. Iankov, M. Schroeder, B. Carlson, K. Bakken, Jann N Sarkaria, J. A. Ecsedy, Antonio D'Assoro, B. Friday, Evanthia Galanis

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Aurora A kinase (AURKA), a member of the serine/threonine kinase family, plays a critical role in cell division, and it is widely overexpressed in a variety of tumors including glioblastoma (GBM). Alisertib (MLN8237) is an orally administered selective AURKA inhibitor with potent antiproliferative activity, currently undergoing clinical testing in different tumor types. In vitro evaluation of alisertib against the primary GBM lines, GBM6, GBM10, GBM12 and GBM39 showed significant antitumor activity with IC50s ranging between 30 and 95 nM. Orthotopic xenografts of GBM10 and the bevacizumab resistant lines GBM6 and GBM39 were established by implantating 3 × 105 cells in the caudate nucleus of nude mice; animals were randomized to treatment with either alisertib 30 mg/kg/day or vehicle. In all three models, treatment with alisertib resulted in a statistically significant prolongation of survival (p < 0.0001). In addition, alisertib administration in these mice decreased phosphorylated aurora-A, induced mitotic arrest and significantly decreased histone H3 phosphorylation in tumors. In conclusion, alisertib displays significant antitumor activity against primary GBM lines and xenografts, including patient derived GBM lines resistant to bevacizumab; these data support clinical translation in GBM.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalJournal of Neuro-Oncology
DOIs
StateAccepted/In press - Nov 5 2016

    Fingerprint

Keywords

  • Alisertib
  • Aurora A
  • Bevacizumab
  • GBM
  • Resistance

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this